Drugs / Candin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03953196 | Apr → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01653249 | Aug 2012 → Jul 2015 | human papilloma virus infection | University of Arkansas | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02393417 | Mar 2015 → Jan 2018 | common wart | Nielsen BioSciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01757392 | Sep 2012 → Dec 2014 | common wart, human papilloma virus infection | Nielsen BioSciences, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05889845 | Jan → Aug 2025 | common wart | Nielsen BioSciences, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05216510 Background | Jan → Sep 2022 | type IV hypersensitivity disease | Tonix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05952934 Comparator | Feb 2024 → Jul 2031 expected | head and neck squamous cell carcinoma | University of Arkansas | Recruiting | No outcome recorded |
| Phase 2 | NCT02481414 Comparator | Nov 2015 → Sep 2022 | cervical intraepithelial neoplasia | University of Arkansas | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANDIN | “Subjects will also receive one intradermal injection (0.1 mL) of a positive control (CANDIN®), and one intradermal injection (0.1 mL) of a negative control "diluent".” NCT05216510 ↗8“This study assessed three dosing schemes using Candin®, a standardized purified Candida antigen (PCA), for the treatment of common warts.” PMID 40155509 ↗ Mar 2025 |
| Known as | Candida albicans Skin Test Antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01757392 ↗ |
| Modality | Other / unclassified | “yeast extract called Candin®” NCT01653249 ↗ |
| Route | Other | “0.3 ml injected intralesionally monthly.” NCT01757392 ↗ |